The 10th Joint meeting of the Americas and European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS)
The following summarizes some of the highlights from Day 1 of MSToronto 2026.
MS risk with infectious mononucleosis
sNfL elevation postpartum
PRLs contribute to treatment failure
Update on frexalimab
Daratumumab effective in AQ4-IgG+ NMOSD
One-quarter of MS patients are untreated
Clinical tip of the day
Read More
MSToronto2026 – 10th Joint ACTRIMS-ECTRIMS meeting – October 21-23, 2026
Wednesday, October 21. 16:30 – 18:30
NeuroSens will be providing daily coverage of MSToronto 2026, the 10th joint ACTRIMS-ECTRIMS meeting, to be held October 21-23 in Toronto, Ontario. You can help us refine our reporting by completing the survey below. Read More
SPECIAL REPORT
Click here to complete the quick poll on DMT preferences.
Submit your responses anonymously to be able to view the aggregate results of the poll.
Patient satisfaction with high-efficacy therapies
Switching therapies
Real-world impact on PIRA
Over 12,000 MS patients in Canada have been treated with ofatumumab, an anti-CD20 monoclonal antibody administered by self-injection, since it was authorized for use five years ago. A Canadian study has now examined patient acceptance of treatment in an analysis of patient support program (PSP) data (Selchen et al. Mult Scler Relat Disord 2026:107:106976). A total of 5436 of 6377 patients in the database met inclusion criteria. Treatment persistence was 96.94% at 12 months, 95.02% at 24 months and 92.26% at 36 months. The most common reasons for treatment discontinuation were side effects (0.9%), conception/pregnancy (0.5%) and patient request (0.5%). Read More